Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives
Helicobacter pylori (H. pylori) is the main cause of gastric adenocarcinoma. However, the traditional antibiotic treatment of H. pylori is limited due to increased antibiotic resistance and low efficacy; low drug delivery efficiency and difficulties in eradicating H. pylori that is present intracell...
Saved in:
| Main Authors: | Yongkang Lai, Wei Wei, Yiqi Du, Jie Gao, Zhaoshen Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2120747 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biomaterials mediated 3R (remove-remodel-repair) strategy: holistic management of Helicobacter pylori infection
by: Tinglin Zhang, et al.
Published: (2025-07-01) -
Stimulus-responsive biomaterials for Helicobacter pylori eradication
by: Tiantian Shan, et al.
Published: (2024-12-01) -
Clinical and Pharmacological Aspects of Resistance to Eradication Therapy of Helicobacter Pylori Infection
by: S. Yu. Serebrova, et al.
Published: (2020-05-01) -
Biological Cost of Helicobacter pylori Rifampicin Resistance
by: K. T. Momynaliev, et al.
Published: (2020-05-01) -
New Approaches to Therapy of Helicobacter pylori Infection (by the Materials of the Maastricht Consensus-IV, Florence, 2010)
by: A. G. Evdokimova, et al.
Published: (2020-05-01)